PMID: 2109563Apr 15, 1990Paper

Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections

Annals of Internal Medicine
S A MilesR T Mitsuyasu

Abstract

To study the efficacy of high doses of beta-ser-interferon (recombinant human 17-serine beta-interferon) in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A nonrandomized, controlled trial of two high-dose regimens of beta-ser-interferon administered until tumor progression, toxicity, or an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection occurred. An AIDS treatment clinic at a tertiary care center. A sequential sample of 39 patients with biopsy-proven, AIDS-related Kaposi sarcoma were enrolled during a 2-year period. Thirty-eight patients were evaluable for response. Most patients (35 of 38) had one or more of the following clinical or laboratory predictors for a poor response to interferon therapy: HIV p24 antigenemia, low CD4 cell numbers, elevated beta 2-microglobulin levels, previous opportunistic infections, or previous systemic chemotherapy. Beta-ser-interferon was self-administered subcutaneously at home 5 days per week. The first 21 patients used 90 million IU/d, and the remainder used 180 million IU/d. Six patients (16%) had a major clinical response, and 15 (39%) had stable disease for prolonged periods. Toxicities were minimal; the major toxicity was a skin r...Continue Reading

Citations

Sep 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M AzaguryG Perie
Oct 29, 2000·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·P A BuchwalderJ Biollaz
May 1, 1994·The Journal of Clinical Investigation·J CorbeilD J Looney
Mar 22, 2007·Expert Opinion on Biological Therapy·Marinella ClericoLuca Durelli
Apr 6, 1999·Cancer Treatment Reviews·G SchwartsmannR U Villarroel
Nov 24, 1999·Journal of the European Academy of Dermatology and Venereology : JEADV·A VirgiliL Sighinolfi
Nov 27, 1999·Journal of Cutaneous Medicine and Surgery·D SassevilleS A Khenaizan
Apr 1, 1992·Clinical and Experimental Immunology·J L Fahey, R Schooley
Oct 1, 1996·The Annals of Pharmacotherapy·A K Morris, A W Valley
Mar 9, 2021·Expert Opinion on Biological Therapy·Mika ScheininMorteza Azhdarzadeh
Jul 1, 1992·Survey of Ophthalmology·S A TeichA H Friedman

❮ Previous
Next ❯

Related Concepts

Related Feeds

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.

AIDS Malignancies (ASM)

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

Related Papers

International Journal of Dermatology
F CnuddeW Rozenbaum
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
U KrainickM Talpaz
© 2021 Meta ULC. All rights reserved